Terazosin polymorph and pharmaceutical composition

Details Terazosin polymorph and pharmaceutical composition Terazosin polymorph and pharmaceutical composition

1993-07-13

1994-03-15

Tsang, Cecilia

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

544291, A61K 31505, C07D40514

Patent

active

052946150

ABSTRACT:
A novel anhydrous crystalline polymorph of 1-(4-amino-6,7-dimethoxy- 2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine monohydrochloride is disclosed, together with pharmaceutical formulations containing the compound. The novel polymorph exhibits a diminished food effect when administered to human subjects.

REFERENCES:
patent: 4026894 (1977-05-01), Winn et al.
patent: 4112097 (1978-09-01), Winn et al.
patent: 4251532 (1981-02-01), Roteman
patent: 5122514 (1992-06-01), Boger et al.
patent: 5212176 (1993-05-01), Kyncl et al.
Yacobi et al, J. Clin. Pharmacol. 21:301-310 (1981).
Tkaker et al, Am. J. Clin. Nuta. 45(6) 1987.
Serajuddin et al, J. Pharm. Sci. 75(1).1986.62-64.
Yakahe Hakhoechi, 22(1), 49-54 (1992).

Affiliated with

Also associated with

Rating

Terazosin polymorph and pharmaceutical composition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Terazosin polymorph and pharmaceutical composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Terazosin polymorph and pharmaceutical composition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1536208